Transurethral resection (TUR) is widely used to manage early-stage bladder cancer. A recent study has confirmed that a second, or restaging, TUR is associated with a lower risk of progression and cancer-related death. Restaging TUR is therefore recommended as a standard of care in patients with stage T1 bladder cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Divrik, R. T., Sahin, A. F., Yildirim, U., Altok, M. & Zorlu, F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur. Urol. 58, 185–190 (2010).
Kulkarni, G. S. et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur. Urol. 57, 60–70 (2009).
Hall, M. C. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178, 2314–2330 (2007).
Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54, 303–314 (2008).
Brausi, M. et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol. 41, 523–531 (2002).
Dutta, S. C. et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J. Urol. 166, 490–493 (2001).
Herr, H. W., Donat, S. M. & Dalbagni, G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J. Urol. 177, 75–79 (2007).
Herr, H. W. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J. Urol. 174, 2134–2137 (2005).
Grimm, M. O. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J. Urol. 170, 433–437 (2003).
Divrik, R. T., Yildirim, U., Zorlu, F. & Ozen, H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J. Urol. 175, 1641–1644 (2006).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Dalbagni, G. Restaging TUR reduces recurrence and progression risk. Nat Rev Urol 7, 649–650 (2010). https://doi.org/10.1038/nrurol.2010.189
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2010.189
This article is cited by
-
T1 bladder cancer: current considerations for diagnosis and management
Nature Reviews Urology (2019)